Cover Image
市場調查報告書

Chiesi Farmaceutici SpA:產品平台分析

Chiesi Farmaceutici SpA - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 207932
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
Chiesi Farmaceutici SpA:產品平台分析 Chiesi Farmaceutici SpA - Product Pipeline Review - 2016
出版日期: 2016年10月12日 內容資訊: 英文 61 Pages
簡介

Chiesi Farmaceutici SpA. 是重視研究的製藥公司,致力於研發呼吸系統、心血管系統,以及罕見疾病的治療藥,並流通於市場中。

本報告提供Chiesi Farmaceutici SpA的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Chiesi Farmaceutici SpA的基本資料

Chiesi Farmaceutici SpA概要

  • 主要資訊
  • 企業資料

Chiesi Farmaceutici SpA:R&D概要

  • 主要的治療範圍

Chiesi Farmaceutici SpA:評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Chiesi Farmaceutici SpA:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式

Chiesi Farmaceutici SpA▼初期階段產品開發中產品

前臨床階段的產品/聯合治療模式

Chiesi Farmaceutici SpA:藥物簡介

  • (beclomethasone dipropionate + formoterol fumarate + glycopyrrolate)
  • meropenem
  • CHF-6001
  • glycopyrrolate
  • CHF-5633
  • Drug for Cystic Fibrosis
  • Small Molecule to Agonize Glucocorticoid Receptor for Asthma and COPD
  • Small Molecule to Inhibit Caspase-2 for Neonatal Brain Injury
  • Small Molecule to target Beta 2 Adrenergic Receptor and Muscarinic Acetylcholine Receptor M3 for Asthma and COPD
  • Small Molecules to Inhibit Neutrophil Elastases

Chiesi Farmaceutici SpA:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Chiesi Farmaceutici SpA:最近的開發平台趨勢

Chiesi Farmaceutici SpA:暫停中的計劃

Chiesi Farmaceutici SpA:開發中止的開發中產品▼開發中止的開發中產品簡介

carmoterol indantadol

Chiesi Farmaceutici SpA:企業發表

Chiesi Farmaceutici SpA:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08152CDB

Summary

Global Markets Direct's, 'Chiesi Farmaceutici SpA - Product Pipeline Review - 2016', provides an overview of the Chiesi Farmaceutici SpA's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Chiesi Farmaceutici SpA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Chiesi Farmaceutici SpA
  • The report provides overview of Chiesi Farmaceutici SpA including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Chiesi Farmaceutici SpA's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Chiesi Farmaceutici SpA's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Chiesi Farmaceutici SpA's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chiesi Farmaceutici SpA
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chiesi Farmaceutici SpA's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Chiesi Farmaceutici SpA Snapshot
    • Chiesi Farmaceutici SpA Overview
    • Key Facts
  • Chiesi Farmaceutici SpA - Research and Development Overview
    • Key Therapeutic Areas
  • Chiesi Farmaceutici SpA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Chiesi Farmaceutici SpA - Pipeline Products Glance
    • Chiesi Farmaceutici SpA - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Chiesi Farmaceutici SpA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Chiesi Farmaceutici SpA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
    • Chiesi Farmaceutici SpA - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Chiesi Farmaceutici SpA - Drug Profiles
    • (beclomethasone dipropionate + formoterol fumarate + glycopyrrolate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • budesonide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CHF-5633 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CHF-6001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CHF-6297 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CPD-15 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Bronchopulmonary Dysplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glycopyrrolate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melatonin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meropenem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Enzymes for Rare Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Neonatal Respiratory Distress Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Target NGF for Undisclosed Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Neutrophil Elastase for Respiratory Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target Beta 2 Adrenergic Receptor and Muscarinic Acetylcholine Receptor M3 for Asthma and COPD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Neonatal Abstinence Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRP-601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • velmanase alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chiesi Farmaceutici SpA - Pipeline Analysis
    • Chiesi Farmaceutici SpA - Pipeline Products by Target
    • Chiesi Farmaceutici SpA - Pipeline Products by Route of Administration
    • Chiesi Farmaceutici SpA - Pipeline Products by Molecule Type
    • Chiesi Farmaceutici SpA - Pipeline Products by Mechanism of Action
  • Chiesi Farmaceutici SpA - Dormant Projects
  • Chiesi Farmaceutici SpA - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • beclomethasone dipropionate SR
      • carmoterol
      • indantadol
      • Porphozym
  • Chiesi Farmaceutici SpA - Company Statement
  • Chiesi Farmaceutici SpA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Chiesi Farmaceutici SpA, Key Facts
  • Chiesi Farmaceutici SpA - Pipeline by Indication, 2016
  • Chiesi Farmaceutici SpA - Pipeline by Stage of Development, 2016
  • Chiesi Farmaceutici SpA - Monotherapy Products in Pipeline, 2016
  • Chiesi Farmaceutici SpA - Combination Treatment Modalities in Pipeline, 2016
  • Chiesi Farmaceutici SpA - Partnered Products in Pipeline, 2016
  • Chiesi Farmaceutici SpA - Partnered Products/ Combination Treatment Modalities, 2016
  • Chiesi Farmaceutici SpA - Out-Licensed Products in Pipeline, 2016
  • Chiesi Farmaceutici SpA - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Chiesi Farmaceutici SpA - Phase III, 2016
  • Chiesi Farmaceutici SpA - Phase II, 2016
  • Chiesi Farmaceutici SpA - Phase I, 2016
  • Chiesi Farmaceutici SpA - Preclinical, 2016
  • Chiesi Farmaceutici SpA - Unknown, 2016
  • Chiesi Farmaceutici SpA - Pipeline by Target, 2016
  • Chiesi Farmaceutici SpA - Pipeline by Route of Administration, 2016
  • Chiesi Farmaceutici SpA - Pipeline by Molecule Type, 2016
  • Chiesi Farmaceutici SpA - Pipeline Products by Mechanism of Action, 2016
  • Chiesi Farmaceutici SpA - Dormant Developmental Projects,2016
  • Chiesi Farmaceutici SpA - Discontinued Pipeline Products, 2016
  • Chiesi Farmaceutici SpA, Subsidiaries

List of Figures

  • Chiesi Farmaceutici SpA - Pipeline by Top 10 Indication, 2016
  • Chiesi Farmaceutici SpA - Pipeline by Stage of Development, 2016
  • Chiesi Farmaceutici SpA - Monotherapy Products in Pipeline, 2016
  • Chiesi Farmaceutici SpA - Combination Treatment Modalities in Pipeline, 2016
  • Chiesi Farmaceutici SpA - Out-Licensed Products in Pipeline, 2016
  • Chiesi Farmaceutici SpA - Pipeline by Top 10 Target, 2016
  • Chiesi Farmaceutici SpA - Pipeline by Route of Administration, 2016
  • Chiesi Farmaceutici SpA - Pipeline by Molecule Type, 2016
  • Chiesi Farmaceutici SpA - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top